Product nameTofacitinib, Janus kinase (JAK) inhibitor
DescriptionPotent, cell-permeable Janus kinase (JAK) inhibitor
Potent, cell-permeable Janus kinase 3 (JAK3) inhibitor with some JAK1 inhibitory activity as well. Pyrrolo[2,3-d]pyrimidine derivative. Blocks downstream STAT signaling resulting in potent inhibition of inflammatory cytokines with resultant immunosuppressive and anti-inflammatory activity.
Storage instructionsShipped at Room Temperature. Store at -20°C. Store under desiccating conditions.
Solubility overviewSoluble in DMSO to 100 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
This product has been referenced in:
- Boyle DL et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis 74:1311-6 (2015). Read more (PubMed: 25398374) »
- Haan C et al. Jak1 has a dominant role over Jak3 in signal transduction through ?c-containing cytokine receptors. Chem Biol 18:314-23 (2011). Read more (PubMed: 21439476) »
- Flanagan ME et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 53:8468-84 (2010). Read more (PubMed: 21105711) »
- Kudlacz E et al. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol 582:154-61 (2008). Read more (PubMed: 18242596) »